M. Huberman

发表

Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial.

P. Benotti, S. Wallach, C. Arkin, 1990, Annals of internal medicine.

Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers.

D. Costa, E. Wong, E. Uhlmann, 2015, Lung cancer.

Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer

Geoffrey R. Oxnard, Ross A. Soo, Matthew Meyerson, 2013, Science Translational Medicine.

Pulse Afatinib for ERBB2 Exon 20 Insertion–Mutated Lung Adenocarcinomas

S. Kobayashi, D. Costa, J. A. Zerillo, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Structural, biochemical, and clinical characterization of Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutations in lung cancer (Science Translational Medicine (2014) 6, (225er1))

M. Meyerson, M. Hanna, L. Sequist, 2014 .

Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma

L. Spence, M. Posner, K. Stuart, 1997, Diseases of the colon and rectum.

Phase II trial of erlotinib in chemotherapy-naive women with advanced pulmonary adenocarcinoma.

T. Lynch, P. Janne, N. Lindeman, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma.

D. Costa, M. Huberman, M. Shea, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non–Small-Cell Lung Cancer

M. Kris, C. Azzoli, J. Shrager, 2021, JCO precision oncology.

P-611 Final results from a phase II study of erlotinib (TarcevaTM) monotherapy in patients with advanced non-small cell lung cancer following failure of platinum-based chemotherapy

J. Rigas, R. Perez-soler, G. Clark, 2003 .

Chest Film Clinic: What caused persistent cough and dyspnea in this patient?

O. Kocher, P. Boiselle, S. Ashiku, 2006 .

Case series of treatment approaches in fit nonagenarians with stage IV non-small-cell lung cancer.

J. Warner, D. Costa, Elizabeth M. Gaughan, 2011, Journal of thoracic disease.

Impact of combined modality therapy on the treatment of adenocarcinoma of the colon.

J. Jessup, G. Steele, P. Busse, 1993, Seminars in surgical oncology.

P3-096: Phase II study of erlotinib in chemo–naïve women with advanced pulmonary adenocarcinoma.

P. Jänne, N. Lindeman, D. Jackman, 2007 .

Rapidly fatal advanced EGFR-mutated lung cancers and the need for rapid tumor genotyping in clinical practice.

D. Costa, E. Folch, D. Rangachari, 2016, Cancer treatment communications.

Influence of multimodality therapy on the management of pancreas carcinoma.

J. Jessup, M. Posner, M. Huberman, 1993, Seminars in surgical oncology.

Efficacy of multimodality therapy in gastric adenocarcinoma.

J. Jessup, G. Steele, M. Posner, 1993, Seminars in surgical oncology.

Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non–small-cell Lung Cancer

D. Costa, G. Weiss, R. Gill, 2020, Clinical Lung Cancer.

Non-human primate (baboon) anti-carcinoembryonic antigen antibody infusion in patients with metastatic adenocarcinoma

A. Monaco, A. Kassis, D. Haagensen, 1986, Cancer Immunology, Immunotherapy.

Improvement of Type 2 Diabetes in a Lung Cancer Patient Treated With Erlotinib

D. Costa, M. Huberman, 2006, Diabetes Care.

Safety and Efficacy of PD‐1 Inhibitors Among HIV‐Positive Patients With Non–Small Cell Lung Cancer

D. Costa, F. Marty, M. Cheng, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase II trial of 5‐fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma

R. Jenkins, W. Lewis, K. Stuart, 1998, Cancer.

Peripheral neurotoxicity of taxol in patients previously treated with cisplatin

G. Cavaletti, G. Tredici, M. Huberman, 1995, Cancer.

Bevacizumab reverses cerebral radiation necrosis.

E. Wong, Xing-Qi Lu, A. Mahadevan, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.

J. Rigas, R. Perez-soler, G. Clark, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of an outpatient regimen of recombinant human interleukin‐2 and alpha‐2a‐interferon in patients with solid tumors

J. Groopman, D. Levitt, J. Zeffren, 1991, Cancer.

Adequacy of Lymph Node Transbronchial Needle Aspirates Using Convex Probe Endobronchial Ultrasound for Multiple Tumor Genotyping Techniques in Non–Small-Cell Lung Cancer

A. Majid, O. Kocher, D. Costa, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized trial of estrogen vs. tamoxifen therapy for advanced breast cancer

J. Lokich, M. Huberman, T. Zipoli, 1985, American journal of clinical oncology.

Hepatic involvement in the cutaneous T‐cell lymphomas. Results of percutaneous biopsy and peritoneoscopy

J. Minna, A. Gazdar, P. Bunn, 1980, Cancer.

Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib

M. Meyerson, P. Jänne, D. Haber, 2006, Clinical Cancer Research.

A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non–Small Cell Lung Cancer

W. Guo, M. Socinski, Kwok-Kin Wong, 2013, Clinical Cancer Research.

5-Fluorouracil and alpha-interferon in hepatocellular carcinoma.

M. Huberman, J. Tessitore, K. Stuart, 1996, American journal of clinical oncology.

Comparison of systemic chemotherapy with hepatic arterial infusion in metastatic colorectal carcinoma.

M. Huberman, 1983, Seminars in oncology.

BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations

D. Tenen, S. Kobayashi, T. Boggon, 2007, PLoS medicine.

Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors

S. Kobayashi, D. Costa, Susumu S. Kobayashi, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.

S. Kobayashi, D. Costa, H. Reddi, 2017, Lung cancer.

De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers.

D. Dias-Santagata, A. Majid, S. Kobayashi, 2016, Lung cancer.

Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation.

S. Kobayashi, D. Costa, S. Schulman, 2015, Lung cancer.

A pilot study of sphincter-sparing management of adenocarcinoma of the rectum.

T. Ravikumar, R. Mayer, J. Jessup, 1991, Archives of surgery.

Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3–PD‐L1 ≥50% Expression in Lung Adenocarcinoma

S. Kobayashi, D. Costa, X. Le, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers.

D. Tenen, S. Kobayashi, D. Costa, 2007, Lung cancer.

Cancer Growth Factor Receptor ( EGFR ) Exon 20 Insertion Mutations in Lung Structural , Biochemical , and Clinical Characterization of Epidermal

M. Meyerson, M. Hanna, L. Sequist, 2013 .

Patterns of care for non-small-cell lung cancer at an academic institution affiliated with a national cancer institute-designated cancer center.

G. Michaud, J. Aronovitz, A. Majid, 2012, Journal of oncology practice.

Erlotinib at a Dose of 25 mg Daily for Non-small Cell Lung Cancers with EGFR Mutations

M. Kris, D. Tenen, W. Pao, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib

P. Jänne, D. Tenen, W. Pao, 2008, Clinical Cancer Research.

Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice.

A. Majid, O. Kocher, D. Costa, 2013, Lung cancer.

Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.

S. Kobayashi, V. Miller, D. Costa, 2015, Clinical lung cancer.

Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practice.

A. Majid, D. Costa, X. Le, 2015, Cancer treatment communications.

EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas

L. Sequist, S. Kobayashi, D. Costa, 2018, Clinical Cancer Research.

A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically De fi ned Advanced Non – Small Cell Lung Cancer

M. Socinski, Kwok-Kin Wong, L. Sequist, 2013 .

Phase II trial of sequential chemotherapy followed by chemoradiation, surgery, and postoperative chemotherapy for the treatment of stage IIIA/IIIB non-small-cell lung cancer.

S. Ou, B. Halmos, A. Muzikansky, 2006, Clinical lung cancer.

Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions

C. Azzoli, L. Sequist, A. Shaw, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer.

A. Majid, O. Kocher, D. Costa, 2014, Lung cancer.

Cetuximab Monotherapy in Patients with Advanced Non-small Cell Lung Cancer After Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy

J. Neal, L. Sequist, P. Fidias, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Trials of 9‐Amino‐20(S)‐Camptothecin in Boston

T. Lynch, L. Shulman, D. Kufe, 1996, Annals of the New York Academy of Sciences.

A phase I study of recombinant human interleukin‐2 and alpha‐interferon‐2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma

J. Groopman, T. Ahmed, A. Mittelman, 1990, Cancer.

Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy.

S. Kobayashi, D. Costa, X. Le, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Uncommon presentations of some common malignancies: Case 1. Sequential paraneoplastic endocrine syndromes in small-cell lung cancer.

O. Kocher, B. Halmos, S. Berman, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preservation of Sphincter Function in Rectal Carcinoma by a Multimodality Treatment Approach

R. Mayer, J. Jessup, P. Busse, 1992 .

A Phase II Study of Oxaliplatin, Pemetrexed, and Bevacizumab in Previously Treated Advanced Non-small Cell Lung Cancer

L. Sequist, P. Fidias, R. Heist, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial

A. Patnaik, D. V. Hoff, E. Rowinsky, 2007, Cancer Chemotherapy and Pharmacology.

Comparison of surgery alone with surgery and adjuvant radiotherapy for pT3N0 prostate cancer

Z. Petrovich, J. Stein, D. Skinner, 2002, BJU international.

Phase II trial of oxaliplatin, pemetrexed, and bevacizumab in previously-treated advanced non-small cell lung cancer (NSCLC)

L. Sequist, R. Heist, J. Temel, 2007 .

EGFR Testing in Advanced Non-Small-Cell Lung Cancer, A Mini-Review.

D. Costa, Y. Sheikine, E. Folch, 2016, Clinical lung cancer.

Tumor biomarker testing in non-small-cell lung cancer: A decade of change.

Adnan Majid, A. Majid, S. Kobayashi, 2018, Lung cancer.

De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors.

A. Majid, D. Costa, X. Le, 2015, Lung cancer.

Correction: EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas

L. Sequist, S. Kobayashi, D. Costa, 2020, Clinical Cancer Research.

Activity of AUY922 in NSCLC patients with EGFR exon 20 insertions.

L. Sequist, J. Engelman, A. Shaw, 2015 .

Etoposide in combination with cytarabine, doxorubicin, and 6-thioguanine for treatment of acute nonlymphoblastic leukemia in a protocol adjusted for age.

S. Wallach, C. Arkin, J. Lokich, 1987, Cancer treatment reports.

A phase I dose escalation study of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358,774 in patients (pts) with advanced solid tumors

R. Hellman, T. Tensfeldt, S. Silberman, 2000 .

Gemcitabine Pulmonary Toxicity: CT Features

P. Boiselle, M. Morrin, M. Huberman, 2000, Journal of computer assisted tomography.

Phase 1-2a Multicenter Dose-Ranging Study of Canfosfamide in Combination with Carboplatin and Paclitaxel as First-Line Therapy for Patients with Advanced Non-small Cell Lung Cancer

T. Kolevska, L. Sequist, P. Fidias, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II study of erlotinib in chemo-naive women with advanced pulmonary adenocarcinoma

P. Jänne, N. Lindeman, D. Jackman, 2007 .

Selection of treatment for patients with early stage non-small cell Lung cancer in a multidisciplinary thoracic oncology program

D. Feller-Kopman, A. Ernst, P. Boiselle, 2007 .

Persistence of dysphagia and odynophagia after mediastinal radiation and chemotherapy in patients with lung cancer or lymphoma.

A. Ng, A. Recht, A. Freedman, 2016, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

Vinblastine plus cisplatin in advanced non-small cell lung cancer: lack of advantage for vinblastine infusion schedule.

J. Lokich, M. Huberman, T. Zipoli, 1986, Cancer treatment reports.

Subdivision of the T1 size descriptor for stage I non-small cell lung cancer has prognostic value: a single institution experience.

M. Decamp, S. Gangadharan, M. Kent, 2009, Chest.

Prospective staging evaluation of patients with cutaneous T-cell lymphomas. Demonstration of a high frequency of extracutaneous dissemination.

J. Minna, A. Gazdar, J. Whang‐Peng, 1980, Annals of internal medicine.